icotinib + gemcitabine

**icotinib + gemcitabine** is a combination therapy consisting of **icotinib**, a first-generation, orally administered, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and **gemcitabine**, a nucleoside analog cytotoxic chemotherapy agent. Icotinib inhibits EGFR tyrosine kinase activity, leading to antiproliferative and antiangiogenic effects in tumor cells, particularly those with EGFR mutations or overexpression. Gemcitabine acts as an antimetabolite, incorporating into DNA during replication and resulting in cell death. This combination has been investigated as first-line therapy in patients with **locally advanced, unresectable, or metastatic pancreatic adenocarcinoma**, and in **untreated non-small cell lung cancer (NSCLC)** harboring EGFR-sensitive mutations, demonstrating promising antitumor activity with acceptable safety profiles.

Brand names

ConmanaGemzar

Other names

icotinib hydrochloride + gemcitabine